Silexion Therapeutics has initiated a regulatory application in Israel for a Phase 2/3 clinical trial of SIL204 in patients with locally advanced pancreatic cancer. The application follows positive feedback from German authorities and preclinical data showing up to 99.7% cancer cell inhibition. Regulatory filings in Germany and the EU are planned for Q1 2026, with U.S. expansion expected post-safety run-in. The trial will evaluate SIL204, an siRNA therapy designed to silence mutated KRAS oncogenes. Silexion aims to address the critical unmet need in pancreatic cancer with limited treatment options. The company is committed to advancing innovative oncology treatments.

Read more at GlobeNewswire: Silexion Therapeutics Announces Submission of Phase 2/3